Mer­ck notch­es 38th ap­proval for Keytru­da, sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer

The FDA on Thurs­day ap­proved Mer­ck’s an­ti-PD-1 ther­a­py to treat a type of gas­troin­testi­nal can­cer in com­bi­na­tion with chemother­a­py, mark­ing the drug’s 38th in­di­ca­tion.

The ap­proval is to treat lo­cal­ly ad­vanced un­re­sectable or metasta­t­ic HER2-neg­a­tive gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma when used in com­bi­na­tion with flu­o­ropy­rim­i­dine- and plat­inum-con­tain­ing chemother­a­py. It marks the drug’s sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER